Fintel reports that on February 14, 2025, Morgan Stanley downgraded their outlook for Galapagos NV - Depositary Receipt () ...

In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...

Shares of Galapagos (NASDAQ:GLPG) (OTCPK:GLPGF) ended a four-day winning streak on Friday after Morgan Stanley downgraded the Belgian biotech, citing its decision to deprioritize its CAR-T therapy ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

Morgan Stanley downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of $22, down from $33.Maximize Your Portfolio ...

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 ...

In its annual results statement, Galapagos chief financial officer Thad Huston said the firm is moving ahead with a planned ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Galapagos NV (NASDAQ:GLPG) stands against the other cheap biotech ...

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...